Evaluation of the impact of levothyroxine treatment on the psychomotor developmental status of three-year-old children born to mothers with mild thyroid impairment; Tehran Thyroid and pregnancy study: study protocol for a randomized clinical trial

Sima Nazarpour, Fahimeh Ramezani Tehrani, Firoozeh Sajedi, Razieh Bidhendi Yarandi and Fereidoun Azizi

Abstract

Background: Despite the known adverse effects of maternal overt hypothyroidism on the neurocognitive development of children, there is uncertainty regarding the impact of gestational thyroid dysfunction or autoimmune thyroiditis on infant/child neurological development. This study aims to evaluate the impact of levothyroxine (LT4) treatment on the psychomotor developmental status of three-year-old children born to mothers with mild thyroid impairment (subclinical hypothyroidism with/without autoimmune thyroiditis).

Methods/Design: This is a follow-up study of the Tehran Thyroid and Pregnancy Study, a randomized trial in which subclinical hypothyroid pregnant women were assigned to an intervention group (treated with levothyroxine) or a control group (received no treatment). The primary outcome for the purpose of the present study is the developmental status of the children, aged three years, in five domains (communication, gross motor, fine motor, problem-solving, and social–personal domains) using the Ages and Stages Questionnaire (ASQ).

Discussion: The study is designed to assess the developmental status of children born to mothers with mild thyroid impairment (subclinical hypothyroidism with/without autoimmune thyroiditis). This study is one of the limited studies available in this field and has the potential to facilitate much-needed information for related public health policies.

Trial registration: Iranian Registry of Clinical Trials, IRCT2017090314849N5. Registered on 11 September 2017. Iranian Registry of Clinical Trials, IRCT2017090414849N6. Registered on 14 October 2017.

Keywords: Neurodevelopmental, Offspring, Protocol, Subclinical hypothyroidism, Pregnancy, Clinical trial

* Correspondence: fah.tehrani@gmail.com; ramezani@endocrine.ac.ir; framezan@post.harvard.edu

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Several studies revealed the distinguishable role of maternal thyroid hormones on all stages of brain cell development [1, 2]. In the first trimester of pregnancy, a time when the embryo’s thyroid is still developing, fetal thyroid hormones are completely dependent on the mother as a source. However, after this stage, the mother and fetus both contribute to this need. Studies revealed the presence of specific nuclear receptors and thyroid hormones in the fetal brain at the eight week of gestation and free T4 in the coelomic and amniotic fluids, under the role of thyroid hormones in early fetal brain development [3].

Both overt hypothyroidism and hyperthyroidism are well-known modifiable risk factors for various fetal-maternal and child outcomes [4, 5]. Data regarding the adverse pregnancy and child outcomes of subclinical forms of thyroid dysfunction or thyroid autoimmunity are inconclusive and treatment benefits in such women are unclear. Despite observational studies reporting significant association between mild gestational thyroid dysfunctions and several pregnancy complications or neurocognitive impairment in the offspring [6–14], treatment of subclinical hypothyroidism (SCH) or hypothyroxenemia have not improved pregnancy outcomes or even cognitive functions in their children in limited randomized clinical trials (RCT) carried out among pregnant women [15–17]. The results of studies on the effects of maternal autoimmune thyroid disorders on cognitive development in children also differ. Pop et al. in 1995 reported that the neurodevelopmental scores of children of TPOAb-positive (TPOAb+) mothers were significantly worse than those with TPOAb-negative (TPOAb−) mothers [18]; in contrast, Williams et al. [19] demonstrated no evidence of an association between maternal TPOAb and TSH levels and neurodevelopmental outcome. Li et al. [11] showed that the intellectual and motor development of children aged 25–30 months is associated with abnormalities of maternal thyroid at 16–20 weeks’ gestation; maternal SCH or euthyroidism with elevated TPOAb titers were found to be predictors of lower motor and intellectual development. Ghassabian et al. [20] showed that higher titers of TPOAbs during pregnancy were associated with an increase in children’s risk of attention deficit/hyperactivity; however, this adverse effect was not observed in the Controlled Antenatal Thyroid Screening (CATS) study [21, 22] that investigated treatment for SCH on childhood cognition and found no differences in IQ at the ages of three years and 9.5 years between children of treated and untreated SCH mothers. In addition, studies by Casey et al. (2017) and Lazarus et al. (2012) showed maternal treatment for SCH did not result in improved cognitive function in children [15, 17].

Hence, considering the fact that the effect of treatment on the development status of offspring is not clear, in this follow-up clinical trial study, we aim to evaluate the impact of levothyroxine (LT4) treatment on the psycho-motor developmental status of three-year-old children born to mothers with mild thyroid impairment (SCH with/without autoimmune thyroiditis).

Methods
Overall trial design
This is the follow-up study from The Tehran Thyroid and Pregnancy Study [23], a two-phase population-based RCT carried out on pregnant women referring to prenatal clinics of Shahid Beheshti University of Medical Sciences. In brief, in the first phase of this study, using a cluster-sampling method, first-trimester pregnant women were screened for thyroid disorders; in the second phase of the study, those with SCH (both TPOAb-positive and -negative) were randomly assigned to be treated with levothyroxine (intervention) or to receive no treatment. The details of the original study have been published before [23].

The Tehran Thyroid and Pregnancy Study was conducted from September 2013 through February 2016. The first phase of this study was a population-based cross-sectional study in which 1746 pregnant women attending the prenatal clinics of Shahid Beheshti University of Medical Sciences were screened for thyroid dysfunction. Overnight blood samples were collected at the first prenatal visit and second (20–24 weeks of gestation) and third (30–34 weeks of gestation) trimesters to measure serum levels of TSH, thyroxine (T4), resin T-uptake (RTU), and TPOAb. Table 1 shows the classification of mothers according to the level of TSH, FT4I, and TPOAb.

At the first prenatal visit, participants were asked to collect three casual morning urine samples (5–10 mL) every other day.

After excluding those with twin pregnancies and those with overt thyroid dysfunction or SCH (n = 127), euthyroid women and those with other types of thyroid dysfunction (n = 1619) were invited for the second phase of

| Table 1 Classification of mothers according to the level of TSH, FT4I, and TPOAb |
|-------------------|---------|--------|----------|
| Classification   | TSH (mIU/L) | FT4I | TPOAb (IU/mL) |
| Euthyroid        | 0.1–2.5   | 1–4.5 | < 50     |
| Overt hyperthyroidism | < 0.1   | > 4.5 | –        |
| SCH              | < 0.1    | 1–4.5 | –        |
| Overt hypothyroidism | > 10    | –     | –        |
| Overt hypothyroidism | > 2.5   | < 1   | –        |
| SCH TPOAb+       | 2.5–10   | 1–4.5 | < 50     |
| SCH TPOAb−       | 2.5–10   | 1–4.5 | > 50     |

TPOAb thyroid peroxidase antibodies, SCH subclinical hypothyroidism
Neurodevelopmental study of offsprings

Both groups of children (aged three years) born to mothers with SCH and/or autoimmune thyroid disease will be invited to participate. In the present study, parents will complete the Ages and Stages Questionnaire to assess the children’s developmental status. The children of those euthyroid TPOAb⁻ women will also be invited to be participate in this follow-up study and serve as controls (Fig. 1).

Participants will be contacted by phone; the aim and purpose of the present study will be explained in detail. An appointment will be arranged for those participants who wish to complete the development assessment. A trained examiner will explain the instructions for completing the questionnaire. All assessments will be performed by one examiner only to maximize reliability. A randomly selected 5% of the completed assessments will be retested in two weeks and double-scored to ensure the reliability; the scores are calculated and a report is generated for the participants to be taken to their parents. If participants need to be given more information about the results or have any questions, they can contact the examiner directly.

In the present study, the ASQ, a parent-report questionnaire, was chosen because it has been proven to be a valid and/or reliable screening test for Iranian infants and children [26]. The ASQ questionnaire assesses the developmental status of children aged 4–60 months (in 19 age groups) in five developmental domains including communication, gross motor skills, fine motor

![Fig. 1 Study flow chart](image-url)
skills, problem-solving, and social–personal domains. It includes six open-ended questions that assess the parents’ concerns such as visual and auditory problems. Each age-specific domain includes six items, scores are in the range of 0–60 in each subscale, and the total score is in the range of 0–300 [27]. The scoring system is based on a 10–5–0 scoring scale (10 points for every “yes,” 5 points for every “sometimes,” and 0 points for every “not yet” answer to the questions). The sum of scores is then compared with a list of age-specific cut-off points standardized for Iranian children [26, 28].

ASQ validity has been examined across different cultures and communities across the world [29–32] and has excellent psychometric properties (test–retest reliability of 92%, sensitivity of 87.4%, and specificity of 95.7%) [26, 29, 31–33]. The inter-rater reliability values obtained were 0.88, 0.91, 0.88, 0.89, and 0.86 for the communication, gross motor skills, fine motor skills, problem-solving, and social–personal domains, respectively, and 0.93 totally [26]. It had the ability to precisely determine developmental disorders in > 96% of children [34].

The study protocol has been designed and reported in line with SPIRIT guidelines, with an attached SPIRIT flow diagram (Fig. 2) and checklist (Additional file 1) [35].

**STUDY PERIOD**

| TIMEPOINT** | -t | 0 | 1st trimester | 2nd trimester | 3rd trimester | Delivery | After 3 years | t+ |
|-------------|----|---|----------------|---------------|---------------|---------|--------------|----|
| ENROLMENT:  |    |   |                |               |               |         |              |    |
| Eligibility screen | X |    |                |               |               |         |              |    |
| Informed consent | X |    |                |               |               |         |              |    |
| Allocation    | X |    |                |               |               |         |              |    |
| INTERVENTIONS:|    |   |                |               |               |         |              |    |
| LT4 treatment | X | X | X               |               |               |         |              |    |
| Placebo       |   |   |                |               |               |         |              |    |
| Euthyroid TPOAb |   |   |                |               |               |         |              |    |
| ASSESSMENTS: |    |   |                |               |               |         |              |    |
| TSH, T4, T-uptake and | X | X | X | X | X |         |              |    |
| TPOAb         | X | X |               |               |               |         |              |    |
| Urine Iodine  |   | X |               |               |               |         |              |    |
| Maternal and neonatal outcomes |   |   |               |               |               |         |              |    |
| ASQ           |   |   |                |               |               |         | X            |    |

**Fig. 2** Summary of study events schedule. TPOAb thyroid peroxidase antibodies, TSH thyroid stimulating hormone, LT4 levothyroxine, ASQ Ages and Stages Questionnaires

**Ethics approval**

Written informed consent will be obtained from all participants by the examiner. It will be emphasized that participation in the study is voluntary and they were free to withdraw from the study at any time.

Both original and current studies have been approved by the Medical Ethics Committee of the Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences and received two separate codes for studies among TPOAb+ women and among SCH TPOAb+ ones (approval code numbers for original study: IR.SBMU.ENDOCRINE.REC.1395.297 and IR.SBMU.RIES.REC.1394.48, approval code numbers for current study IR.SBMU.ENDOCRINE.REC.1395.299 and IR.SBMU.ENDOCRINE.REC.1395.300). They also were registered in the Iranian Randomized Clinical Trials (IRCT) Registry (trial codes for original study: IRCT2013100114849N1, IRCT2013112014849N2, and IRCT2013121214849N3; trial codes for current study: IRCT2017090414849N6 and IRCT2017090314849N5).

**Power calculation and sample size justification**

The purpose of this study will be multiple comparisons of five groups: three groups of controls: no intervention
TPOAb−, no intervention TPOAb−, and healthy; as well as two cases: intervention TPOAb+ and TPOAb−. We will consider five primary outcomes: communication; gross motor skills; fine motor skills; problem-solving; and social–personal aspects.

Post-hoc power calculation was done to detect samples needed. It has been shown that, with power of 80% and type one error of 5%, nearly 2356, 590, 263, 149, 96, 67, 50, 39, and 31 participants are required to find the effect sizes 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9 statistically significant. We will consider q = 15% attrition as well which increases sample size by \( n^* = n/1-q \). The following formula for comparison of groups is applied:

\[
n \geq \frac{\left(1 + \sqrt{g-1}\right) \left(\frac{z_1 \times z_1 + z_1 \times \beta}{d^2}\right)^2 + \frac{z_1^2 \times \sqrt{g-1}}{2 + (1 + \sqrt{g-1})}}{\left(1 + \sqrt{g-1}\right)}
\]

### Randomization and blinding

The pregnant women who participated in the original Tehran Thyroid and Pregnancy Study, with a diagnosis of SCH and/or autoimmune thyroid diseases, were randomly allocated into two groups using a computer-generated list in blocks of four. For the purpose of the current study, the trained examiner who assesses the developmental status of children born from those pregnant women using the ASQ are blinded to the previous grouping of participants.

### Statistical analysis

**Intention to treat (ITT) analysis** will be considered to deal with non-compliance and missing outcomes in our RCT.

Dataset accuracy will be checked using histograms and cross-tabulations to identify any outliers and errors. We will also run “Grubbs” test, an ESD (method extreme studentized deviate), to determine whether any values are significant outliers or implausible values > 4 SD from the mean will be considered as outliers and discarded. Descriptive statistics will be presented as means ± SD for normal, medians and IQR for non-normal variables, and categorical variables presented as percent.

Normality assumption will be checked by Kolmogorov–Smirnov and Shapiro–Wilk test; in case of rejection, the Mann–Whitney non-parametric U test will be applied, otherwise independent Student’s t test will be used to find the differences. For categorical variables, chi-squared test and/or Fisher’s exact test in case of a sparse data problem (cell < 5) will be used. Subgroup analysis for important confounding variables will be run, if needed.

The primary analysis for the study is to assess the effect of treatment on the aspects of psychomotor developmental status. Therefore generalized linear models (GLM) will be conducted modeling the variables and checking the causal relationships between the outcome of interests and other covariates such as treatment. Crude and adjusted models for potentially confounding effects will be fitted.

Interaction effect of treatment and some other covariates will be added to the model and a subgroup analysis will be run to check the effect of treatment on the levels of covariates, variables such as parity, socioeconomic status, type of delivery, lactic status, urinary iodine, and so on.

Since our study follows up the second generation of the ancestors whom intake the intervention, the casual relationships could be assessed via transitional models. There is a series of statistical analyses to estimate these relationships; we use transitional models which applied Markov Chains stochastic process and multistate models.

Statistical analysis will be performed using STATA software (version 10; STATA, Inc., College Station, TX, USA) and the latest version of R CRAN, the “msm” package, to analyze multi-state modelling with R; \( p < 0.05 \) is considered statistically significant.

### Results

Baseline characteristics of neonates according to their mothers’ thyroid status are presented in Table 2.

| Characteristics                  | SCH-TPOAb− | Placebo | SCH-TPOAb+ | Placebo | Euthyroid TPOAb− |
|----------------------------------|------------|---------|------------|---------|------------------|
|                                  | LT4 treatment (\( n = 183 \)) | Placebo (\( n = 183 \)) | LT4 treatment (\( n = 65 \)) | Placebo (\( n = 66 \)) | Euthyroid TPOAb− (\( n = 1028 \)) |
| Gestational age, mean (SD)       | 38.03 (1.4) | 37.9 (1.5) | 39.3 (1.3) | 38.4 (1.7) | 39.4 (1.4)       |
| Birth weight, mean (SD)          | 3190.82 (455.13) | 3203.1 (497.1) | 3139.1 (287.6) | 3127.7 (523.5) | 3236.6 (448.8)   |
| Birth height, mean (SD)          | 50.1 (2.3) | 50.2 (2.7) | 49.5 (1.7) | 50.3 (1.5) | 50.1 (2.3)       |
| Birth head circumference, mean (SD) | 34.6 (1.4) | 34.7 (1.6) | 34.5 (1.1) | 34.9 (1.4) | 34.7 (2.3)       |
| TSH (\( \mu U/mL \)), Median (IQR) | 1.1 (0.5–2.1) | 1.1 (0.5–1.9) | 1.3 (0.45–1.9) | 1.0 (43–1.9) | 0.90 (0.4–1.7)   |

**SCH** subclinical hypothyroidism, TPOAb thyroid peroxidase antibodies, TSH thyroid-stimulating hormone, LT4 levothyroxine
Discussion

Principal findings

SCH has been associated with several obstetric complications [36–38], but there is no direct evidence that levothyroxine therapy reduces these risks, especially in those without thyroid autoimmunity or those been identified using the cut-off value of 2.5 μIU/mL. Conflicting results have been reported regarding the association between subclinical thyroid dysfunctions during pregnancy and neurodevelopmental disorders in their offspring [7, 8, 11, 12, 14, 39, 40]. There is currently no evidence that levothyroxine treatment of pregnant women with SCH, especially when initiated after seven weeks of gestation, improves neurocognitive functions in offspring [15–17]. As a result, neither association has recommended universal screening for SCH or thyroid autoimmunity during pregnancy, considering the lack of robust evidence for the benefit from screening and treating mild thyroid insufficiency [41, 42].

There are limited RCTs with sufficient sample sizes that have assessed the beneficiary effect of administration of levothyroxine in pregnant women with SCH in terms of neurocognitive developments [17, 43, 44]. These studies mainly suffer from lack of initiation of treatment in early gestation (before the fetal thyroid gland become functional), do not consider the influencing effect of iodine deficiency (the association between mild thyroid dysfunction and intellectual disability seen in observational study and may be mediated by iodine deficiency and hence not completely ameliorated by levothyroxine), lack precision of the thyroid tests that have been utilized for categorization of the study participants, and do not report whether it includes those with thyroid autoimmunity.

The key strength of the present study is assessing the neurodevelopmental status of the offspring of both groups of TPOAb+ cases and SCH-TPOAb– women along with euthyroid TPOAb– women, considering their iodine sufficiency status during pregnancy. We are not aware of any other studies that have considered all these components simultaneously. The other strength of this study will be the rate of attrition; however, its pilot study received a response rate of >80%. The other challenge of this study is lack of awareness of other factors that may influence the developmental status of the children, e.g. nutritional inadequacies [50], although the randomized allocation of study participants minimizes this effect.

By conducting this study, we hope to better understand the beneficiary impact of treatment of mild forms of thyroid dysfunctions during pregnancy, considering the influential effect of iodine status. This piece of knowledge has the potential for evidence-based decision-making regarding the universal screening for thyroid dysfunction and/or thyroid autoimmunity.

In summary, this is the follow-up study of the Tehran Thyroid and Pregnancy Study; a two-phase population-based RCT that aimed to assess the developmental status of children born to mothers with mild thyroid impairment, in terms of SCH with/without autoimmune thyroiditis.

Trial status

Protocol numbers: IRCT2017090314849N5 and IRCT 2017090414849N6.

Patient recruitment is currently ongoing.

Study start date: September 2017.

Primary completion date: February 2019.

Study completion date: March 2019.

Additional file

Additional file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb)

Abbreviations

ASQ: Ages and Stages Questionnaire; CATS: Controlled Antenatal Thyroid Screening; FT4i: Free Thyroxin Index; IQ: Intelligence quotient; LT4: Levothyroxine; SCH: Subclinical hypothyroidism; SD: Standard deviation; TPOAbs: Thyroid peroxidase antibodies; TSH: Thyroid-stimulating hormone, thyrotropin, thyrotropic hormone

Acknowledgements

The authors wish to acknowledge Ms. Niloofar Shiva for critical editing of English grammar and syntax of the manuscript. The authors would like to thank laboratory staff of RIES.

Funding

This study was financially supported by Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Availability of data and materials
The datasets generated and/or analyzed during the current study will be made available from the corresponding author.

Authors’ contributions
SN: Study design, execution, analysis, manuscript drafting, and critical discussion. FRT: Study design, execution, analysis, manuscript drafting, and critical discussion. FS: Study design and critical discussion. RBY: Study design and critical analysis. FA: Study conception and design, interpretation of data, and critical revision. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval has been granted by the Medical Ethics Committee of the Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences (approval code numbers: IR.SBMU.ENDOCRINE.REC.1395.299 and IR.SBMU.ENDOCRINE.REC.1395.300).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Midwifery, Varamin-Pishva Branch, Islamic Azad University, Tehran, Iran. 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Pediatric Neurorehabilitation Research Center, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran. 4Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 5Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 12 September 2018 Accepted: 11 December 2018
Published online: 28 January 2019

References
1. Ahmed OM, El-Gareib A, El-Bakry A, El-Tawab SA, Ahmed R. Thyroid hormones states and brain development interactions. Int J Dev Neurosci. 2008;26(2):147–209.
2. Morreale de Escobar G, Obregón MJ, Escobar del Rey F. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothryoxinemia? J Clin Endocrinol Metab. 2000;85(11):3975–87.
3. Vulsma T, Gons M, de Vijlder J. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med. 1989;321:13–6.
4. Kriass K, Poppe K, Glimoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702–55.
5. Sajedi F, Vameghi R, Bandmiri M, Alijaz V, Hemmati Gorgani S, Shahshahanipour S. Motor developmental delay in 7500 Iranian infants: prevalence and risk factors. Iran J Neurol. 2009;3(3):43–50.
6. Alabovitch M, Arino N, Barbour LA, Cobin RH, De Groot LJ, Glimoer D, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92(8 Suppl9):S1–47.
7. El Baba KA, Azar ST. Thyroid dysfunction in pregnancy. Int J Gen Med. 2012;5:227.
8. Glimoer D, Rash M, Grin J, Kinhaert J. Risk of subclinical hypothyroidism in pregnant women with autoimmune antithyroid antibodies. J Clin Endocrinol Metab. 1994;79(1):197–204.
9. Glimoer D, Salazar M, Bourdon P, Lejeune B, Delange F, Lemone M, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1993;71(3):421–7.
10. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341(18):549–55.
11. Li Y, Shan Z, Teng W, Yu X, Li Y, Fan C, et al. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months. Clin Endocrinol. 2010;72(6):825–9.
12. Pop VJ, Kuijpers A, van Baar AL, Verkerk G, van Son MM, de Vlijde JJ, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol. 1999;50(2):149–55.
13. Smit B, Kok J, Vulsma T, Briet J, Boer K, Wiersinga W. Neuropsychological development of the newborn and young child in relation to maternal thyroid function. Acta Paediatr. 2002;91(3):291–5.
14. Williams F, Watson J, Ogston S, Hume R, Williams P, Visser T, Scottish Preterm Thyroid Group. Mild maternal thyroid dysfunction at delivery of infants born ≤34 weeks and neurodevelopmental outcome at 5.5 years. J Clin Endocrinol Metab. 2012;97(6):1977–85.
15. Casey BM, Thorn EA, Peaceman AM, Varner MW, Sorkin Y, Hirtz DG, et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N Engl J Med. 2017;376(9):815–25.
16. Hershman JM. Levothyroxine therapy of subclinical hypothyroidism or hypothyroxinemia in pregnancy does not improve cognitive function in the offspring. Clin Endocrinol. 2017;86(4):132–5.
17. Lazarus JH, Bestwick JP, Shannon C, Paridece R, Maina A, Rees P, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012;366(6):493–501.
18. Pop VJ, de Vries E, van Baar AL, Waelkens J, Hume R, Horsten M, et al. Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? J Clin Endocrinol Metab. 1995;80(12):3561–6.
19. Williams FL, Watson J, Ogston SA, Visser TJ, Hume R, Williams P. Maternal and umbilical cord levels of T4, FT4, TSH, TPOAb, and TgAb in term infants and neurodevelopmental outcome at 5.5 years. J Clin Endocrinol Metab. 2013;98(2):629–39.
20. Ghassabian A, Bongers-Schokking JJ, De Rijke YB, Van Mill N, Jaddoe VV, de Munick Keizer-Schrama SM, et al. Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. Thyroid. 2012;22(2):178–86.
21. Bath SC, Rayman MP. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012;366(7):1640–1.
22. Hales C, Taylor PN, Shannon S, Paridece R, McEwan K, Zhang L, et al. Controlled Antenatal Thyroid Screening is effective in detecting maternal subclinical hypothyroidism in children. J Clin Endocrinol Metab. 2018;103(4):1583–91.
23. Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Azizi F. Thyroid and Pregnancy in Tehran, Iran: Objectives and Study Protocol. Int J Endocrinol. 2016;14(1):e33477.
24. Nazarpour S, Tehrani FR, Simbar M, Tohidi M, Majid HA, Azizi F. Effects of levothyroxine treatment on pregnancy outcomes in pregnant women with autoimmune thyroid disease. Eur J Endocrinol. 2012;167(2):253–65.
25. Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Minooee S, Rahmati M, et al. Effects of levothyroxine on pregnant women with subclinical hypothyroidism, negative for thyroid peroxidase antibodies. J Clin Endocrinol Metab. 2017;103(3):926–35.
26. Vameghi R, Sajedi F, Mojemiari AK, Habibollahi A, Lornezhad HR, Delavari B. Cross-cultural adaptation, validation and standardization of Ages and Stages Questionnaire (ASQ) in Iranian children. Iran J Public Health. 2013;42(5):522.
27. Singh A, Yeh CJ, Blanchard SB. Ages and stages questionnaire: a global screening scale. Biol Med Hosp Infant Mex. 2017;74(1):5–12.
28. Sajedi F, Vameghi R, Kraskian Mujembari A. Prevalence of undetected developmental delays in Iranian children. Child Care Health Dev. 2014;40(3):379–88.
29. Heo HK, Squires J, Youvanoff P. Cross-cultural adaptation of a pre-school screening instrument: comparison of Korean and US populations. J Intellect Disabil Res. 2008;52(3):195–206.
30. Otavalo AM, Grañena N, Gaeto N, Torres MA, Zamblera MN, Vasconez MA, et al. ASQ-3: Validation of the Ages and Stages Questionnaire (ASQ) in Argentine children. Arch Argent Pediatr. 2018;116(1):7–13.
31. Salihong P. Use of screening instrument in Northeast Thai early childcare settings. Procedia Soc Behav Sci. 2010;7:97–105.
32. Sarmiento Campos JA, Squires J, Ponte J. Universal developmental screening: preliminary studies in Galicia, Spain. Early Child Dev Care. 2011;181(4):475–85.
33. Sajedi F, Vameghi R, Habibollahi A, Lornejad H, Delavar B. Standardization and validation of the ASQ developmental disorders screening tool in children of Tehran city. Tehran Univ Med Sci. 2012;70(7):436–46.

34. Soleymani F, Vameghi R, Dadkhah A. High risk infants referred to healthcare centers in North and East of Tehran and risk factors of motor developmental delay. Hakim Res J. 2009;12(2):11–18.

35. Chan A-W, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–2.

36. Benhadi N, Wiersinga W, Reitsma J, Vrijkotte T, Bonsel G. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol. 2009;160(6):985–91.

37. Chen L-M, Du W-J, Dai J, Zhang Q, Si G-Y, Yang H, et al. Effects of subclinical hypothyroidism on maternal and perinatal outcomes during pregnancy: a single-center cohort study of a Chinese population. PLoS One. 2014;9(10):e109364.

38. Wilson KL, Casey BM, McIntire DD, Halvorson LM, Cunningham FG. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstet Gynecol. 2012;119(2):315–20.

39. Behrooz HG, Tohidi M, Mehrabi Y, Behrooz EG, Tehranidoost M, Azizi F. Subclinical hypothyroidism in pregnancy: intellectual development of offspring. Thyroid. 2011;21(10):1143–7.

40. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. Obstet Gynecol Surv. 2000;55(1):3.

41. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J. 2014;3(2):76–94.

42. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081–125.

43. Hales C, Channon S, Taylor PN, Draman MS, Muller I, Lazarus J, et al. The second wave of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive assessment protocol. BMC Endocr Disord. 2014;14(1):95.

44. Spong C. Thyroid therapy for mild thyroid deficiency in pregnancy. Clinical Trials. https://clinicaltrials.gov/ct2/show/NCT00388297. Last accessed 26 Jul 2013.

45. Group MTF-USC. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114(3):289–99.

46. Yu LM, Hey E, Doyle LW, Farrell B, Spark P, Altman DG, et al. Evaluation of the Ages and Stages Questionnaires in identifying children with neurosensory disability in the Magpie Trial follow-up study. Acta Paediatr. 2007;96(12):1803–8.

47. Elbers J, Macnab A. The Ages and Stages Questionnaires: feasibility of use as a screening tool for children in Canada. Can J Rural Med. 2008;13(1):9.

48. Klamer A, Lando A, Pinborg A, Greisen G. Ages and Stages Questionnaire used to measure cognitive deficit in children born extremely preterm. Acta Paediatrica. 2005;94(9):1327–9.

49. Squires J, Katzerv A, Jenkins F. Early screening for developmental delays: Use of parent-completed questionnaires in Oregon’s Healthy Start Program. Early Child Dev Care. 2002;172(3):275–82.

50. Prado EL, Dewey KG. Nutrition and brain development in early life. Nutr Rev. 2014;72(4):267–84.